These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31062995)

  • 1. Desogestrel versus antagonist injections for LH suppression in oocyte donation cycles: a crossover study.
    Martínez F; Rodriguez-Purata J; Beatriz Rodríguez D; Clua E; Rodriguez I; Coroleu B
    Gynecol Endocrinol; 2019 Oct; 35(10):878-883. PubMed ID: 31062995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study.
    Martínez F; Rodriguez-Purata J; Clua E; Garcia S; Coroleu B; Polyzos N
    Gynecol Endocrinol; 2019 Oct; 35(10):884-889. PubMed ID: 31081407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does LH suppression by progesterone-primed ovarian stimulation compared with GnRH antagonist affect live birth rate among oocyte recipients?
    Martínez F; Clúa E; García S; Coroleu B; Polyzos NP; Barri PN
    Reprod Biomed Online; 2020 May; 40(5):661-667. PubMed ID: 32268981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
    Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
    Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.
    Wang HL; Lai HH; Chuang TH; Shih YW; Huang SC; Lee MJ; Chen SU
    PLoS One; 2016; 11(4):e0154123. PubMed ID: 27100388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.
    Beguería R; García D; Vassena R; Rodríguez A
    Hum Reprod; 2019 May; 34(5):872-880. PubMed ID: 30927417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone-primed ovarian stimulation in oocyte donation: a model for elective fertility preservation?
    Devesa M; Racca A; Clúa E; Casato C; García S; Polyzos NP; Martínez F
    Reprod Biomed Online; 2022 Jun; 44(6):1015-1022. PubMed ID: 35339364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medroxyprogesteron acetate use to block LH surge in oocyte donor stimulation].
    Crha I; Ventruba P; Filipinská E; Dziakova M; Žáková J; Ješeta M; Lousová E; Papíková Z
    Ceska Gynekol; 2018; 83(1):11-16. PubMed ID: 29510633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
    Benchabane M; Santulli P; Maignien C; Bourdon M; De Ziegler D; Chapron C; Gayet V
    Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):83-88. PubMed ID: 28368800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
    JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzis BC; Tournaye H; Devroey P
    Fertil Steril; 2011 Nov; 96(5):1112-5. PubMed ID: 21924414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.